A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty.

J Pain Res · 2017 · PMC5638571 · PMID 29062240

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Similarly, over 0–4, 0–8, 0–12, and 0–24 hours, the difference in the morphine treatment groups between stage I and II did not reach statistical significance ( Figure S2A–D ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.